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Outcomes Study Cognitive Functioning-Revised [MOS COG-R]; PHQ-9, Patient Global 
Impression of Severity [PGIS] and Change [PGIC]; SF-36 Health Survey [SF-36], Lam 
Employment Absence and Productivity Scale [LEAPS], Sheehan Disability Scale 
[SDS] and Work Productivity and Activity Impairment: Specific Health Problem 
[WPAI:SHP]. Results: The study population consisted of 855 subjects at baseline 
(418 US and 437 UK), with MDD patients representing 49% of the sample in each 
country; 169 and 153 MDD patients were invited for the follow-up in the US and 
UK, respectively. Internal consistency was high for the total scale and for the four 
proposed subscales (Attention, Retrospective memory, Prospective memory, and 
Planning), with Cronbach’s alpha ranging from 0.81 to 0.96. Convergent validity was 
supported by strong correlations with other measures of cognitive functioning (0.8 
Pearson’s coefficient) and moderate correlations with several construct measures 
known to be associated with cognitive functioning, including health-related quality 
of life, productivity at work, and other functional impairment (Pearson’s coefficients 
ranging from 0.3 to 0.6), and by substantial differences in scores in subgroups known 
to differ in cognitive functioning impairment. The PDQ-D was also responsive to 
changes in depression symptom severity. Confirmatory factor analyses supported 
the scoring of a global scale for perceived cognitive functioning. ConClusions: The 
PDQ-D is a reliable, valid and responsive instrument for assessing MDD patients’ 
perception of deficits related to cognitive functioning.
RESEARCH POSTER PRESENTATIONS – SESSION I 
DISEASE-SPECIFIC STUDIES
INDIvIDUAl’S HEAlTH – Clinical Outcomes Studies
PIH1
MOTHERS’ OwN MIlk FOR THE FEEDINg OF PRETERM INFANTS: A SySTEMATIC 
lITERATURE REvIEw
Garcia-Stewart S., Mitchell S.A.
Abacus International, Bicester, UK
objeCtives: To conduct a systematic review to examine the incremental benefits 
of mothers’ own milk (MM), with or without fortification, compared with donor 
milk (DM) and/or preterm formula (PF) for the nutritional support of preterm 
infants both in the neonatal intensive care unit (NICU) and following hospital dis-
charge. Methods: English-language studies published post-1990 were identified 
from electronic databases (Medline, EMBASE and Cochrane Library) and confer-
ence proceedings. Eligible studies enrolled infants with mean gestational age less 
than 35 weeks with no restriction on geographical location. Results: Thirty-three 
unique studies met eligibility criteria: United States (n= 12), Canada (n= 2), Australia 
(n= 2), Mexico (n= 1), Israel (n= 2), Europe (n= 13) or multinational (n= 1). There was 
a paucity of both RCT data (n= 7) and studies which reported exclusive use of MM 
feeding (n= 3). In addition, there was considerable heterogeneity between studies 
with regard to study design, duration of follow up and amounts of MM ingested, and 
a robust meta-analysis was therefore not feasible. However, a significant beneficial 
effect for MM over DM and/or PF for the incidence of sepsis, necrotizing enterocolitis 
(NEC) and longer-term neurodevelopment was reported in a number of individual 
studies. With regard to anthropomorphic outcomes of body weight, length and 
head circumference, there was no clear consensus on the effect of feeding regi-
men. Sixteen studies reported the relationship between the dose of MM received 
and outcomes; increased MM dosages in the feeding regimen were associated with 
significantly lower rates of sepsis, NEC, and hospital readmissions, reduced NICU 
costs, and improved neurodevelopment. ConClusions: Exclusive or high-dose 
MM with or without fortification is associated with short- and long-term beneficial 
effects in preterm infants. These results confirm MM to be the optimal nutrition for 
preterm infants and stress the importance of developing comprehensive strategies 
to overcome the challenges of providing MM and improving breastfeeding rates in 
preterm infants in the NICU.
PIH2
UTERINE-SPARINg SURgICAl TREATMENT MODAlITIES IN wOMEN wITH 
UTERINE FIbROIDS: A SySTEMATIC REvIEw AND INDIRECT TREATMENT 
COMPARISON
Panagiotopoulou N.1, Nethra S.1, Karabis A.2, Ahmad G.1, Burls A.3
1Pennine Acute Hospitals NHS Trust, Manchester, UK, 2Mapi – HEOR & Strategic Market Access, 
Houten, The Netherlands, 3City University London, London, UK
objeCtives: To evaluate the safety and effectiveness of conservative sur-
gical treatments for uterine fibroids in women who wish to preserve their 
uterus. Methods: A systematic literature search of electronic databases 
(MEDLINE, EMBASE, CENTRAL) and grey literature up to October 2012 identified 5 
RCTs (436 patients): 2 comparing uterine artery embolization (UAE) with myomec-
tomy (MYO) and 3 comparing UAE with laparoscopic uterine artery occlusion 
(LUAO). Primary outcome measures included patients’ satisfaction, re-intervention 
and ovarian failure rate. Secondary outcomes were clinical failure, hysterectomy 
and complication rates, hospitalization and recovery times, pregnancy rate, preg-
nancy complications and live-birth rate. Standard and network meta-analysis 
were performed on relevant outcomes. Results: Of the three most popular 
uterine-sparing surgical treatments for fibroids, network meta-analysis showed 
that MYO and UAE resulted in higher rates of patient satisfaction and lower rates 
of clinical failure than LUAO in the first year after treatment [OR 2.56, 95%CrI 0.56- 
11.75, P(better)= 11% and 2.7, 95%CrI 1.1- 7.14, P(better)= 1%; 0.29, 95%CrI 0.06- 1.46, 
P(better)= 7% and 0.37, 95%CrI 0.13- 0.93, P(better)= 2% respectively]. Moreover, MYO 
resulted in lower re-intervention and hysterectomy rates than UAE and LUAO [0.08, 
95%CrI 0.02- 0.27, P(better)< 1%, 0.08, 95%CrI 0.01- 0.37 P(better)< 1%); 0.16, 95%CrI 
0.01-0.85 P(better)= 2%, 0.15 95%CrI 0- 8.74 P(better)= 16% respectively] even though 
the later techniques had an advantage over MYO due to shorter hospitalization 
and quicker recovery. There was no evidence of convincing difference between the 
three techniques in the number of women experiencing ovarian failure, minor or 
major complications. However, MYO may lead to better conception outcomes in 
absolute error was on average 0.15 but was considerably high (> 0.34) if the observed 
EQ-5D value was below 0.5. Sensitivity analysis revealed that different EQ-5D value 
sets resulted in different algorithms but similar predicting ability. ConClusions: 
Our study showed that there are conceptual differences between the CCQ and EQ-5D 
and mapping should be considered as second-best option compared to directly 
collected EQ-5D data. Furthermore, the mapping performance seems to depend on 
the severity of the study population.
Ql2
MEASURINg PATIENT-RElEvANT TREATMENT bENEFIT IN DERMATOlOgy – 
DEvElOPMENT AND vAlIDATION OF THE SHORT QUESTIONNAIRE “PATIENT 
bENEFIT INDEx 2.0”
Blome C.1, von Usslar K.1, Augustin M.2
1University Medical Center Hamburg, Hamburg, Germany, 2University Medical Center Hamburg-
Eppendorf, Hamburg, Germany
objeCtives: Evidence on patient-relevant treatment benefit is the main criterion 
for reimbursement decisions in many European countries. Usually, an increase of 
quality of life (QoL) during treatment is used as benefit indicator. The Patient Benefit 
Index (PBI) method, in contrast, evaluates benefit retrospectively: Before treatment, 
patients rate importance of treatment goals; after treatment, they rate goal achieve-
ment. This prevents any bias due to response shift which has repeatedly been found 
in pre-post QoL assessment. Here, we developed a short PBI version (“PBI 2.0”) appli-
cable to different skin diseases. Methods: Treatment goal items for the PBI 2.0 
were developed based on nine validated disease-specific PBI versions. Items were 
tested for content, completeness, and comprehensiveness in qualitative interviews 
with n= 16 patients with atopic dermatitis, leg ulcers, psoriasis, and vitiligo. Items 
were revised on basis of patient feedback. The PBI 2.0 was tested for convergent 
validity, completeness, and congruence with disease-specific PBI versions in a cross-
sectional study on n= 379 patients with the above-mentioned diagnoses. Results: 
The 74 disease-specific items could be condensed to 15 pilot items. Based on the 
qualitative interviews, we could reduce to 12 items. The majority of patients rated 
the PBI 2.0 to be comprehensible (93-98%, depending on diagnosis group), readable 
(94-100%), easy to answer throughout (78-90%), and complete (65-88%). Treatment 
goals mentioned as missing mostly concerned goals unrelated to benefit of medical 
treatment (e.g. information on the disease). The percentage of missing values ranged 
from 0.0% to 2.9%. PBI 2.0 preference-weighted global scores correlated significantly 
with QoL as measured with Dermatology Life Quality Index and EQ-5D (r= 0.19 to 
0.58). Convergent validity of the PBI 2.0 and the respective – about twice as long – 
disease-specific versions were equal, except for the vitiligo version. ConClusions: 
The PBI 2.0 is a qualitatively and quantitatively validated short questionnaire on 
patient-relevant treatment benefit in dermatology.
Ql3
THE MEASUREMENT OF HEAlTH-RElATED QUAlITy OF lIFE: gERMAN 
FINDINgS FROM THE MUlTI-INSTRUMENT COMPARISON (MIC) STUDy
Schlander M.1, Khan M.A.2, Iezzi A.2, Maxwell A.2, Richardson J.2
1University of Heidelberg, Wiesbaden, Germany, 2Monash University, Melbourne, Australia
objeCtives: Different multi-attribute utility (MAU) instruments are known to pro-
duce different values for “utility” and measure different constructs, despite the 
common label “utility”. To date, the Multi-Instrument Comparison (MIC) project has 
been the largest comparative study of health and well-being instruments under-
taken worldwide. Here we report the first results from the German branch of the 
study. Methods: A total of 1269 German respondents (either healthy or suffering 
from defined chronic disorders, i.e., asthma, arthritis, cancer, depression, diabetes, 
hearing loss, heart disease) were recruited and participated in the study, completing 
various MAU instruments, including the EQ-5D, SF-6D, HUI3, 15D, QWB, AQoL(-4D 
and-8D). Cross-validation tests drew heavily on correlation. Preliminary findings, 
based upon Pearson correlation coefficients (indicating the extent to which changes 
in one variable correspond with changes in another), showed low correlations 
between measures of utility and measures of subjective well-being. While prefer-
ences might differ from subjective well-being, their correlation might be higher. 
Hence, a better measure should be intraclass correlation (ICC). Results: Intraclass 
correlations between MAU instruments ranged from to 0.8 (HUI3 vs. AQoL-8D) to 
0.4 (AQoL-4D vs. 15D). Linear regression results, reflecting the comparative perfor-
mance of the various MAU instruments with regard to changes in measured utilities 
(as applied in standard cost utility analysis), and detailed results including pair-
wise comparisons of instruments, especially as to sensitivity to changes in a given 
dimension, will be presented. ConClusions: A major conclusion of the present 
study is that, despite some similarity in the mean scores, the instruments tested are 
dissimilar with regard to virtually all other criteria used to compare them. In effect, 
each instrument appears to measure a different construct of “health”. Implications 
for the presumably “generic” measurement of “utility” may be far reaching and will 
be discussed.
Ql4
PSyCHOMETRIC vAlIDATION OF PERCEIvED DEFICITS QUESTIONNAIRE – 
DEPRESSION (PDQ-D) IN PATIENTS wITH MAjOR DEPRESSIvE DISORDER (MDD)
Lam R.W.1, Saragoussi D.2, Danchenko N.3, Rive B.4, Lamy F.X.5, Brevig T.6
1University of British Columbia, Vancouver, BC, Canada, 2Lundbeck SAS, ISSY LES MOULINEAUX 
CEDEX, France, 3Lundbeck SAS, Issy-les-Moulineaux, France, 4Lundbeck S.A.S., Issy-Les 
Moulineaux, France, 5Lundbeck S.A.S., Issy-les-Moulineaux, France, 6H. Lundbeck A/S, Valby, 
Denmark
objeCtives: The Perceived Deficits Questionnaire (PDQ) provides a self-report 
measure of cognitive dysfunction. The current work aims at assessing the psycho-
metric properties of the PDQ adapted for MDD (PDQ-D). Methods: A non-inter-
ventional, online panel survey with baseline assessment and 6-week follow-up 
of US and UK residents (aged ≥ 18 years) with and without MDD [diagnosed with 
depression by a physician and current Patient Health Questionnaire-9 (PHQ-9) 
score ≥ 10]. In addition to PDQ-D, the following instruments were included: Medical 
